The Respiratory Inhaler market report published by Market Data Forecast provides a detailed account of the Market Trends via Customized Research presented as Strategic Analyses, Company Profiles, Competitive Landscape, etc. According to the report the Respiratory Inhaler market is estimated to be USD XX billion in 2017 and predicted to rise to USD XX billion by 2022 with a CAGR of 4.20%. The market is segmented by Product (Dry Powder Inhaler, Metered Dose Inhaler, Nebulizer (Compressed Air Nebulizers, Ultrasonic Nebulizers, Mesh Nebulizers)), Technology (Manually Operated Inhaler Devices, Digitally Operated Inhaler Devices), and Disease Indication (Asthma, COPD, Pulmonary Arterial Hypertension, Others Respiratory Disease. Further the market is also geographically segmented into North America, Europe, Asia-Pacific, Latin America and Middle-East & Africa.
Respiratory inhaler devices are medical instruments that are used to diagnose people with patient suffering from breathing problems arising from respiratory disorders such as COPD, fibrosis, asthma, and ARDS and others.
The rising prevalence of COPD, asthma, chronic respiratory diseases, and other respiratory diseases are anticipated to boost the growth of the Global respiratory inhaler market. With the growing trend of combined therapies among patients due to associated benefits such as more reliable in complex patients, increased efficacy coupled with favorable reimbursement policies associated with therapy is further expected to aid the market growth. Be that as it may, factors such as a dire shortage of skilled pulmonologist, physicians and nurses coupled with lack of awareness among patients in developing nations, absence of a single effective inhaler devices for a variety of disease indication, side effects and complications during drug inhalation, coupled with high prices of inhaler devices are factors restraining market growth.
The global Respiratory Inhaler market is segmented on the basis of Product, Technology and Disease Indication. On the basis of Product, the market is segmented into Dry Powder Inhaler, Metered Dose Inhaler, and Nebulizer. The Nebulizer segment is further sub-segmented into Compressed Air Nebulizers, Ultrasonic Nebulizers, and Mesh Nebulizers. On the basis of Technology, the market is segmented into Manually Operated Inhaler Devices, and Digitally Operated Inhaler Devices. On the basis of Disease Indication, the market is segmented into Asthma, COPD, Pulmonary Arterial Hypertension, and Others Respiratory Disease.
On the basis of geography, the Respiratory Inhaler market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East and Africa. As of 2017, North America is estimated to account for the major share of the overall respiratory inhaler devices market. Asia Pacific is expected to witness the highest growth rate in the coming years.
The market is dominated by companies like AstraZeneca, Beximco Pharmaceuticals Ltd., Boehringer Ingelheim GmbH, Cipla Ltd., GlaxoSmithKline plc, Koninklijke Philips N.V., Merck & Co., Inc., OMRON Healthcare Europe B.V., PARI Medical Holding and Teva Pharmaceutical Industries Ltd.
Browse through the full report at https://www.marketdataforecast.com/market-reports/respiratory-inhaler-market-6366/ and checkout our recent reports in the Medical Devices at https://www.marketdataforecast.com/subcategory/medical-devices-2/ For more insights and up-to-date industry news don’t forget subscribing to our newsletters.